Generic Drug Therapeutic Class: Neurology-Psychiatry
active ingredients: Memantine
laboratory: H. Lundbeck A / S
Bottle (+ dosing pump) of 50 ml
Treatment of adult patients with moderate to severe Alzheimer's disease.
Dosage EBIXA 5 mg / pressure Oral solution Bottle (+ dosing pump) 50 ml
Treatment should be initiated and supervised by a physician trained in the diagnosis and treatment of dementia Alzheimer's disease.
Treatment should begin only with the assurance of the availability of a care worker who will regularly monitor the patient's intake of the drug. The diagnosis must be established according to the criteria in force. The safety and posology of memantine should be re-evaluated at regular intervals, preferably within 3 months of starting treatment. Then, the clinical benefit of memantine and its tolerance should be re-evaluated at regular intervals according to clinical criteria. Maintenance treatment can be continued as long as the therapeutic benefit is favorable and the patient tolerates memantine treatment. Stopping treatment with memantine should be considered when it becomes clear that there is no longer any therapeutic benefit or if the patient does not tolerate treatment.
The maximum dose is 20 mg once a day. To reduce the risk of adverse effects, this dose is achieved by a 5 mg weekly increase in dosage during the first three weeks, as follows:
Week 1 (Days 1-7)
The patient should take 0.5 ml of solution (ie 5 mg) equivalent to one pressure per day for 7 days.
Week 2 (days 8-14)
The patient should take 1 ml of solution (ie 10 mg) equivalent to two pressures a day for 7 days.
Week 3 (days 15-21)
The patient should take 1.5 ml of solution (15 mg) equivalent to three pressures per day for 7 days.
From week 4
The patient should take 2 ml of solution (ie 20 mg) equivalent to four pressures once a day.
The recommended maintenance dose is 20 mg daily.
Based on clinical studies, the recommended dose for patients over 65 years of age is 20 mg daily (2 ml solution, equivalent to four pressures) as described above.
In patients with mild renal impairment (creatinine clearance 50-80 ml / min), no dose adjustment is required. In patients with moderate renal impairment (creatinine clearance 30-49 ml / min), the daily dose should be 10 mg (1 ml solution, equivalent to two pressures). If tolerance is good after at least 7 days of treatment, the dose may be increased up to 20 mg daily following the usual dosing schedule. In patients with severe renal impairment (creatinine clearance between 5 and 29 ml / min), the daily dose should be 10 mg (1 ml solution, equivalent to two pressures).
In patients with mild to moderate hepatic impairment (Child-Pugh A and Child-Pugh B) no dose adjustment is required. No data on the use of memantine in patients with severe hepatic impairment are available. Administration of Ebixa is not recommended for this type of patients.
Children and adolescents
No data available.
Ebixa should be taken orally once a day, at the same time each day. The solution can be taken during or outside meals. The solution should not be poured or pumped directly into the mouth from the vial or pump but must be dosed into a spoon or into a glass of water using the pump.
For detailed instructions on preparing and handling the product, see the section Instructions for use, handling, and disposal .
Hypersensitivity to the active substance or to any of the excipients listed under Composition .
Ebixa side effects
Summary of the security profile
In clinical trials in mild-to-severe dementia involving 1784 Ebixa-treated patients and 1595 placebo-treated patients, the overall frequency of adverse events for Ebixa did not differ from that of placebo; adverse events were generally of mild to moderate intensity. The most common adverse events with a higher incidence in the Ebixa group compared to the placebo group were: dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%) constipation (4.6% vs. 2.6%), somnolence (3.4% vs. 2.2%) and hypertension (4.1% vs. 2.8%).
Tabulated list of adverse reactions
Adverse effects in the table below were collected during clinical trials with Ebixa and since marketing.
Adverse reactions are classified by system organ class using the following conventions: very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1000, <1/100) ), rare (≥ 1/10 000, <1/1000), very rare (<1 / 10, 000), not known (can not be estimated from the available data). Within each frequency group, adverse effects are presented in descending order of severity.
ORGAN SYSTEM CLASS
Infections and infestations
Immune system disorders
Hypersensitivity to the drug
Not known frequency
Psychotic reactions 2
Nervous system disorders
Respiratory, thoracic and mediastinal disorders
Not known frequency
Elevation of liver function tests
Not known frequency
General disorders and administration site conditions
1 Hallucinations have been observed mainly in patients with severe Alzheimer's disease.
2 Isolated cases reported during pharmacovigilance follow-up.
Alzheimer's has been associated with cases of depression, suicidal thoughts and suicide. In post marketing surveillance, these reactions have been reported in patients treated with Ebixa.
Reporting of suspected adverse reactions
The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system - see Annex V.